Kazia Therapeutics Limited
KZIA
$13.25
$3.1931.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.70K | 773.70K | 1.52M | 1.52M | 1.52M |
| Total Other Revenue | 1.13M | 625.30K | 128.70K | 121.40K | 113.90K |
| Total Revenue | 1.16M | 1.40M | 1.65M | 1.64M | 1.63M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.16M | 1.40M | 1.65M | 1.64M | 1.63M |
| SG&A Expenses | 5.67M | 7.48M | 9.31M | 9.13M | 8.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.42M | 15.56M | 20.73M | 20.56M | 20.33M |
| Operating Income | -9.26M | -14.16M | -19.08M | -18.92M | -18.69M |
| Income Before Tax | -14.52M | -16.68M | -18.91M | -18.38M | -17.76M |
| Income Tax Expenses | -1.11M | -639.30K | -178.70K | -178.70K | -177.70K |
| Earnings from Continuing Operations | -13.41 | -16.04 | -18.73 | -18.20 | -17.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.41M | -16.04M | -18.73M | -18.20M | -17.58M |
| EBIT | -9.26M | -14.16M | -19.08M | -18.92M | -18.69M |
| EBITDA | -8.30M | -13.04M | -17.85M | -17.69M | -17.47M |
| EPS Basic | -6.48K | -10.40K | -14.34K | -15.33K | -16.29K |
| Normalized Basic EPS | -7.07 | -12.86 | -18.65 | -19.67 | -20.63 |
| EPS Diluted | -6.48K | -10.40K | -14.34K | -15.33K | -16.29K |
| Normalized Diluted EPS | -7.07 | -12.86 | -18.65 | -19.67 | -20.63 |
| Average Basic Shares Outstanding | 4.38M | 3.62M | 2.85M | 2.48M | 2.11M |
| Average Diluted Shares Outstanding | 8.60K | 7.10K | 5.60K | 4.80K | 4.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |